IMPLICATIONS FOR PATIENT CARE: We have identified a targeted α-radiopharmaceutical therapy with a high preclinical therapeutic window for treatment of HER2-expressing advanced breast cancer. The gene discussed is ERBB2; the disease is breast cancer.